Gland Pharma Ltd — Insulin Exporter Profile
Indian Pharmaceutical Exporter · #4 for Insulin · $4.0M export value · DGFT Verified
Gland Pharma Ltd is the #4 Indian exporter of Insulin with $4.0M in export value and 81 verified shipments. Gland Pharma Ltd holds a 5.3% market share in Insulin exports across 4 countries.
Gland Pharma Ltd — Insulin Export Profile: Buyers & Destinations
Where Does Gland Pharma Ltd Export Insulin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| PAKISTAN | $2.9M | 72 | 84.6% |
| SINGAPORE | $205.5K | 5 | 6.1% |
| KOREA,REPUBLIC OF | $162.6K | 4 | 4.8% |
| SOUTH KOREA | $150.0K | 3 | 4.4% |
| UNITED STATES | $580 | 4 | 0.0% |
| PANAMA | $36 | 3 | 0.0% |
| FRANCE | $10 | 1 | 0.0% |
Gland Pharma Ltd exports Insulin to 7 countries. The largest destination is PAKISTAN accounting for 84.6% of Gland Pharma Ltd's Insulin shipments, followed by SINGAPORE (6.1%) and KOREA,REPUBLIC OF (4.8%). These destinations reflect Gland Pharma Ltd's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Insulin from Gland Pharma Ltd?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ELI LILLY PAKISTAN (PRIVATE) LTD | PAKISTAN | $1.2M | 34 |
| ELI LILLY PAKISTAN (PVT ) LTD | PAKISTAN | $1.1M | 25 |
| LILLY KOREA LTD | KOREA,REPUBLIC OF | $312.6K | 7 |
| ELI LILLY PAKISTAN (PVT ) LTD, | PAKISTAN | $300.4K | 8 |
| LILLY KOREA LIMITED | SOUTH KOREA | $205.5K | 5 |
| ELI LILLY PAKISTAN (PVT) LTD | PAKISTAN | $200.0K | 4 |
| ELI LILLY PAKISTAN PVT LTD | PAKISTAN | $50.0K | 1 |
| CIVICA RX INC, | UNITED STATES | $386 | 2 |
| LIFESCIENCE LOGISTICS | UNITED STATES | $194 | 1 |
| FARMACAM C O J CAIN PANANA PACIFICO | PANAMA | $36 | 3 |
Gland Pharma Ltd supplies Insulin to 12 buyers globally. The largest buyer is ELI LILLY PAKISTAN (PRIVATE) LTD (PAKISTAN), followed by ELI LILLY PAKISTAN (PVT ) LTD (PAKISTAN) and LILLY KOREA LTD (KOREA,REPUBLIC OF). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Insulin Export Value and How Much Does Gland Pharma Ltd Contribute?
India exported $52.4M worth of Insulin through 2,532 shipments from 188 suppliers to 111 countries, serving 384 buyers globally. Gland Pharma Ltd contributes $4.0M to this total, accounting for 5.3% of India's Insulin exports. Gland Pharma Ltd ships Insulin to 7 countries through 12 buyers.
What Is the Average Shipment Value for Gland Pharma Ltd's Insulin Exports?
Gland Pharma Ltd's average Insulin shipment value is $50.0K per consignment, based on 81 shipments totaling $4.0M. The largest destination is PAKISTAN (84.6% of Gland Pharma Ltd's Insulin exports).
How Does Gland Pharma Ltd Compare to Other Indian Insulin Exporters?
Gland Pharma Ltd ranks #4 among 188 Indian Insulin exporters with a 5.3% market share. The top 3 exporters are WOCKHARDT LIMITED ($22.7M), M. J. BIOPHARM PRIVATE LIMITED ($15.2M), GLAND PHARMA LTD ($4.0M). Gland Pharma Ltd processed 81 shipments to 4 destination countries.
What Insulin Formulations Does Gland Pharma Ltd Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| BIPHASIC ISOPHANE INSULIN INJECTION IP,30%, SOLUBLE INSULIN AND 70% ISOPHANE INSULIN, MONOCOMPONENT HUMAN INSULIN (RECOM | $923.0K | 25 |
| BIPHASIC ISOPHANE INSULIN INJECTION IP,30% SOLUBLE INSULIN AND 70% ISOPHANE INSULIN,MONOCOMPONEMT HUMAN INSULIN(RECOMBI | $450.0K | 9 |
| BIPHASIC ISOPHANE INSULIN INJECTION IP,30% SOLUBLE INSULIN AND 70% ISOPHANE INSULIN, MONOCOMPONEMT HUMAN INSULIN(RECOMB | $254.5K | 6 |
| ISOPHANE INSULIN HUMAN SUSPENSION USP,MONOCOMPONENT HUMAN INSULIN(RECOMBINANT DNA ORIGIN) 100 USP INSULIN UNITS/ML,10ML | $214.4K | 6 |
| ISOPHANE INSULIN HUMAN SUSPENSION USP,MONOCOMPONENT HUMAN INSULIN(RECOMBINANT DNA ORIGIN)100 USP INSULIN UNITS/ML 10ML V | $211.8K | 6 |
| BIPHASIC ISOPHANE INSULIN INJECTION IP,30% SOLUBLE INSULIN&70% ISOPHANE INSULIN,MONOCOMPONEM T HUMAN INSULIN(RECOMBINAN | $200.4K | 6 |
| Biphasic Isophane Insulin Injection IP 30% Soluble Insulin and 70% Isophane Insulin, Monocomponent Human Insulin (recomb | $200.0K | 4 |
| INSULIN HUMANM INJECTION USP,MONOCOMPONENT HUMAN INSULIN (RECOMBINANT DNA ORIGIN)100IU USP INSULIN HUMAN UNITS/ML 10 ML | $103.8K | 3 |
| INSULIN HUMANM INJECTION USP,MONOCOMPONENT HUMAN INSULIN(RECOMBINANT DNA ORIGIN)100 IU USP INSULIN HUMAN UNITS/ML 10ML | $102.2K | 3 |
| SOLUBLE INSULIN INJECTION IP,MONOCOMPONEMT HUMAN INSULIN(RECOMBINANT DNA ORIGIN)100 IU/ML,10ML VIAL (HUMULIN R (REGULAR | $100.0K | 2 |
Gland Pharma Ltd exports 30 distinct Insulin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is BIPHASIC ISOPHANE INSULIN INJECTION IP,30%, SOLUBLE INSULIN with 25 shipments worth $923.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
How Does Gland Pharma Ltd Compare to Nearest Insulin Exporters?
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | WOCKHARDT LIMITED | $22.7M | 454 | 25 | $50.0K |
| 2 | M. J. BIOPHARM PRIVATE LIMITED | $15.2M | 303 | 23 | $50.0K |
| 4 | GLAND PHARMA LTD ★ | $4.0M | 81 | 4 | $50.0K |
| 3 | M J BIOPHARM PRIVATE LIMITED | $3.8M | 75 | 15 | $50.0K |
| 5 | ANGEL BIOGENICS PRIVATE LIMITED | $1.7M | 47 | 4 | $35.9K |
Gland Pharma Ltd ranks #4 among 188 Indian Insulin exporters. Average shipment value of $50.0K compared to the market average of $278.5K. The closest competitors by value are WOCKHARDT LIMITED and M. J. BIOPHARM PRIVATE LIMITED.
Which Indian Ports Ship Insulin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 704 | 27.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 646 | 25.5% |
| Bombay Air | 177 | 7.0% |
| Bombay Air Cargo | 123 | 4.9% |
| NHAVA SHEVA SEA (INNSA1) | 108 | 4.3% |
| DELHI AIR | 76 | 3.0% |
| BANGALORE ACC (INBLR4) | 69 | 2.7% |
| JNPT | 68 | 2.7% |
Market Intelligence
Latest developments and market context
Detailed market intelligence for Insulin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Insulin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Gland Pharma Ltd matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 92 individual customs records matching Gland Pharma Ltd exporting Insulin, covering 30 formulations to 7 countries via 12 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 111+ countries, 384+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Insulin Export Data from Gland Pharma Ltd
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Gland Pharma Ltd's Insulin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Gland Pharma Ltd
Company Profile
0 products · $0 total trade · 0 categories
Insulin Stats
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Gland Pharma Ltd.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Insulin. For current shipment-level data, contact TransData Nexus.